Immunomodulators:still having a role?

作     者：Jeffery M.Venner Charles N.Bernstein 

作者机构：University of Manitoba IBD Clinical and Research CentreWinnipegManitobaCanada Department of Internal MedicineMax Rady College of MedicineRady Faculty of Health SciencesUniversity of ManitobaWinnipegManitobaCanada 

出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)

年 卷 期：2022年第10卷第1期

页      面：178-187页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported in part by the BinghamChair in Gastroenterology 

主　　题：immunomodulators 6-mercaptopurine(6-MP) azathioprine Crohn’s disease methotrexate 

摘      要：Immunomodulators,particularly the thiopurines and to a lesser extent methotrexate,were standard of care for inflammatory bowel diseases,including Crohn’s disease and ulcerative colitis,for40 *** there has been a renaissance in available therapies with the advent of biologics and small molecules,an impetus remains for the ongoing use of thiopurines and *** is particularly true for the maintenance of remission and when used in combination therapy with infliximab to suppress anti-biologic *** article summarizes the data behind immunomodulator use in Crohn’s disease,focusing on the beneficial role these drugs still have while acknowledging their clinical limitations.